Atomo partners with Access Bio to develop the world’s first integrated hepatitis C rapid test for self-testing

Today, in a joint press release, Access Bio Inc. and Atomo Diagnostics have announced the development of a best-in-class rapid diagnostic test (RDT) for screening for hepatitis C virus (HCV). It is expected that the new self-tests, along with a professional use version, will be made commercially available later this year.

The partnership has seen Access Bio develop the highly accurate HCV test assay, for which Atomo Diagnostics has created calibrated, fully integrated test devices.  The resulting single-use HCV tests offer unmatched performance and ease-of-use for point of care and self-testing.

Founder and CEO of Atomo Diagnostics, John Kelly, said, “We are delighted to have worked with Access Bio on this tremendously exciting project.  The lack of HCV self-tests to date has been due to the fact that errors are common with standard, multi-component RDT kits that are difficult to use… Self-testing is an area where Atomo has particular expertise, having recently secured the first and only approval for an HIV self-test from the Australian TGA.  We have already demonstrated that our integrated RDT platforms meet the needs of self-testers, and we are confident that this new HCV test can have a significant and positive effect on infection rates globally.”

Read the full press release >